AXDX Accelerate Diagnostics Dashboard

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

Company profile

Ticker

AXDX

Exchange

NASDAQ

Website

acceleratediagnostics.com/

CEO

John Phillips

Incorporated

Delaware

Location

Arizona

Fiscal year end

Dec 31

Sector

Manufacturing > Analytical Laboratory Instrument Manufacturing

Industry (SIC)

Laboratory Analytical Instruments

Agilent • Bio-Rad Laboratories • Avantor • Waters • Illumina • Bruker • Coherent • Mettler-Toledo International • Pacific Biosciences of California • Harvard Bioscience ...

Former names

ACCELR8 TECHNOLOGY CORP

SEC CIK

0000727207

Corporate docs

Articles of Incorporation & Bylaws

IRS number

841072256

AXDX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Renaissance Of The Moonshot Era

2 Mar 21

Investing in Potentially World-Altering Innovation

Top 30 High Short Interest Stocks As Of Friday, Feb. 26, 2021 (Via HighShortInterest.com)

26 Feb 21

Data from https://highshortinterest.com/ GameStop (GME) - 41.22% Short Interest Tanger Factory Outlet Centers (SKT) - 39.98% Academy Sports & Outdoors (ASO) - 37.18% Rocket Companies (RKT) - 35.73% Gogo

Accelerate Diagnostics Q4 EPS $(0.33) Misses $(0.32) Estimate, Sales $3.10M Miss $4.12M Estimate

23 Feb 21

Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.32) by 3.13 percent. The company reported quarterly sales of $3.10 million which

Earnings Scheduled For February 23, 2021

23 Feb 21

Top 30 High Short Interest Stocks As Of Wednesday, Feb. 10, 2021 (Via HighShortInterest.com)

10 Feb 21

Press releases

Pro users get this 30m faster

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2020 Financial Results

23 Feb 21

TUCSON, Ariz., Feb. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2020.

Accelerate Diagnostics, Inc. to Host Earnings Call

23 Feb 21

NEW YORK, NY / ACCESSWIRE / February 23, 2021 / Accelerate Diagnostics, Inc. (NASDAQ:AXDX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 4:30 PM

Accelerate Diagnostics schedules call to review 2020 fourth quarter and full year results

1 Feb 21

TUCSON, Ariz., Feb. 1, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Tuesday, February 23, 2021, at 4:30 p.m. Eastern Time to review 2020

Levi & Korsinsky, LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and other Brokers on Behalf of Investors of AXDX and other stocks Who Were Prevented from Trading

28 Jan 21

Thinking about buying stock in AMC Entertainment, GameStop, Express, Accelerate Diagnostics, or Remark Holdings?

27 Jan 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

1 Mar 21

19 Apr 21

31 Dec 21

Financial summary

Financial statements Chart AXDX financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	35.78M	35.78M	35.78M	35.78M	35.78M	35.78M
Cash burn (monthly)	(positive/no burn)	2.1M	6.3M	6.52M	3.45M	4.2M
Cash used (since last report)	n/a	7.61M	22.81M	23.59M	12.48M	15.2M
Cash remaining	n/a	28.17M	12.97M	12.19M	23.3M	20.58M
Runway (months of cash)	n/a	13.4	2.1	1.9	6.8	4.9

Beta Read what these cash burn values mean

Recent insider trades

AXDX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Apr 21	Patience John	Common Stock	Grant	Aquire A	Yes	No	7.68	21,701	166.66K	4,343,883
9 Apr 21	Miller Mark C	Common Stock	Grant	Aquire A	Yes	No	7.68	13,020	99.99K	26,040
9 Apr 21	Strobeck Matthew	Common Stock	Grant	Aquire A	Yes	No	7.68	19,531	150K	187,297
9 Apr 21	Phillips Jack	Common Stock	Grant	Aquire A	No	No	7.68	4,340	33.33K	19,188
9 Apr 21	Brown Thomas D	Common Stock	Grant	Aquire A	No	No	7.68	8,680	66.66K	37,860

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

AXDX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

15.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	112	-98.2%
Opened positions	1	112	-99.1%
Closed positions	111	0	NEW
Increased positions	1	0	NEW
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	17.67M	287.86M	-93.9%
Total shares	9.35M	27M	-65.4%
Total puts	0	245.1K	EXIT
Total calls	0	80.8K	EXIT
Total put/call ratio	–	3.0	–

Largest owners	Shares	Value	Change
Cowen Prime Services	7.58M	$4.29M	NEW
CS Credit Suisse	1.77M	$13.38M	+6.9%

Largest transactions	Shares	Bought/sold	Change
Cowen Prime Services	7.58M	+7.58M	NEW
Oracle Investment Management	0	-4.09M	EXIT
BLK Blackrock	0	-2.23M	EXIT
Chicago Capital	0	-1.97M	EXIT
AXAHF Axa	0	-1.8M	EXIT
Vanguard	0	-1.64M	EXIT
Griffin Asset Management	0	-1.44M	EXIT
FMR	0	-1.43M	EXIT
Cannell Peter B & Co	0	-1.12M	EXIT
Baird Financial	0	-951.39K	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Thermo Fisher Scientific • Danaher • Luminex • Interpace Biosciences • Bruker • Opgen • GenMark Diagnostics • T2 Biosystems

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: administered, Africa, Aid, annum, APIC, Ascend, assay, assist, assistance, backup, benchtop, BioCheck, breath, Brown, carryback, certainty, chain, chemiluminescence, childcare, closure, complement, CPT, crime, deadly, depositor, detrimental, Dickensen, disability, disbursement, distancing, doubled, duration, effort, EMEA, evidencing, fewer, flat, forgiven, foundation, freestanding, furloughed, hinder, home, host, IgG, IgM, immunoassay, Imputation, impute, insignificant, interaction, John, Joint, legacy, lender, loan, MALDI, Matthew, menu, Miller, mitigate, mitigated, mortgage, NaN, nationwide, nonqualified, Nonretirement, obligor, occasionally, outbreak, outpatient, overwhelmed, owed, package, pandemic, Patience, Paycheck, people, PhenoAST, PhenoPrep, Phoenix, physical, population, Postemployment, PPP, promissory, prudent, Relief, remotely, resume, salary, SBA, serology, situation, small, spread, stable, Strobeck, succeed, sweeping, talented, Task, TCJA, transport, travel, tuition, unchanged, uncollectible, vacation, water, week, wholly, workforce, world, Wuhan

Removed: adjust, allocation, analyst, anniversary, assume, attestation, bargaining, callable, comparability, Consumer, consummated, continually, COSO, customized, cycle, dated, DDx, deadline, disposition, doubtful, Ernst, existed, expressed, faced, favor, formulation, gaining, headcount, impairing, incidence, indirect, LLP, macroeconomic, necessarily, OpTest, outlook, periodic, persuasive, pertain, producing, progressed, publish, purported, quantitative, realize, recovering, repeal, respiratory, retained, retrospective, Sage, SG, sick, smaller, Street, Supplementary, thereto, transition, turbulence, underwriting, underwritten, unexercised, unproven, unqualified, urine, violate, Wall, warrant, yeast, Young

From filing 10-K 2020 FY